替吉奥胶囊联合奈达铂及紫杉醇治疗远处转移鼻咽癌疗效观察  

Clinical Efficacy of Compound Tegafur Capsule Plus Nedaplatin and Paclitaxel in Treatment of Patients with Distant Metastatic Nasopharyngeal Carcinoma

作　　者：李远东[1] 吴灿[1] 余汉毅[1] 许晓峰[2] 黄壬峰[2] 

机构地区：[1]广东医学院附属韶关医院肿瘤科,广东韶关512000 [2]广东医学院附属韶关医院放疗科,广东韶关512000

出　　处：《肿瘤防治研究》2011年第11期1296-1298,共3页Cancer Research on Prevention and Treatment

摘　　要：目的评价替吉奥胶囊(compound tegafur capsule,S-1)联合奈达铂(NDP)及紫杉醇(PTX)方案治疗晚期鼻咽癌的临床疗效及不良反应。方法治疗晚期远处转移鼻咽癌患者21例,给予S-180 mg/m2,分2次,餐后口服,d1～14;NDP80 mg/m2及PTX135 mg/m2静脉滴注,第1天;每4周为1周期,所有患者均治疗2～4周期,按RECIST1.1标准评价客观疗效和不良反应。结果 CR3例(14.3%),PR12例(57.1%),SD5例(23.8%),PD1例(4.8%),RR71.4%。该方案最主要的不良反应为骨髓抑制,Ⅲ～Ⅳ度粒细胞减少占71.5%;Ⅱ～Ⅲ度血小板下降占52.3%,其余不良反应则可以耐受。结论替吉奥联合奈达铂、紫杉醇治疗晚期远处转移鼻咽癌的近期临床疗效较好,不良反应可以耐受,值得临床进一步研究验证。Objective To evaluate the efficacy and toxicity Compound tegafur capsule（S-1） plus Nedaplatin and Paclitaxel（SNP） regimen in the treatment of distant metastatic nasopharyngeal carcinoma.Methods Twenty-one patients with distant metastatic nasopharyngeal carcinoma were enrolled and treated with S-1 capsule 80 mg/m2 twice daily for 14 days plus nedaplatin 80 mg/m2 and paclitaxel 135 mg/m2 by intravenous drip on d1.Treatment was administered every 3 weeks for 2~4 cycles.Results The total effective rate was 71.4%.Three cases were complete response（14.3%）,12 cases were partial response（57.1%）,5 cases was stable disease（23.8%）,1 case were progressing disease（4.8%）.The main adverse effect was myelosuppression,such as grade Ⅲ~Ⅳ neutropenia in 71.5% of all cases and grade Ⅱ~Ⅲ thrombocytopenia in 52.3% of all cases.Other adverse effects could be tolerated.Conclution SNP regimen was a safe and effective therapy for patients with metastatic nasopharyngeal carcinoma although the long-term effects still need further evaluation.

关 键 词：鼻咽肿瘤 替吉奥胶囊 奈达铂 紫杉醇 

分 类 号：R739.63[医药卫生—肿瘤]